Clinical trials: Diffuse Parenchymal Lung Diseases
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma
Q702 for the Treatment of Patients With Hematologic Malignancies
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents.
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06712810
- Testing
- Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Mayo Clinic
ANCA-associated Vasculitis
Abatacept in ANCA Associated Vasculitis
The purpose of this study is to investigate whether abatacept can prevent relapse in patients with ANCA associated vasculitis(AAV). This is a randomised double blinded placebo controlled trial.
- Trial name
- ABAVAS (NCT00482066)
- Testing
- Abatacept (Orencia)
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Imperial College London
Pulmonary Fibrosis, Lung Cancer
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
The goal of this study is to investigate the safety of [68Ga]CBP8 and its efficacy to detect collagen deposition in pulmonary fibrosis.
- Trial name
- NCT03535545
- Testing
- [68Ga]CBP8, PET Imaging
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Pulmonary Fibrosis
Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.
- Trial name
- NCT07229716
- Testing
- HRS-9813 Capsule, Nintedanib Soft Capsules, Pirfenidone Tablets
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Lung Diseases, Lung Cancer
Cough Capture as a Portal Into the Lung
The lung is a privileged organ; blood does not reflect most lung processes well, if at all. Therefore, for population scale diagnostics, the investigator team is developing non-invasive portals to the lung, for eventual early…
- Conditions
- Lung Diseases, Lung Cancer, Lung Diseases, Obstructive, Lung Diseases, Interstitial
- Trial name
- CC1 (NCT05854563)
- Testing
- Observational only, all subjects; measure DNA mutation and proteomic survey.
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Albert Einstein College of Medicine
Rheumatoid Arthritis, Interstitial Lung Disease
Novel Biomarkers in Assessment of Interstitial Lung Disease Associated With Rheumatoid Arthritis Patients
Assess Krebs von den Lungen-6 (KL-6) and Calprotectin as novel biomarkers for diagnosis of ILD among Rheumatoid arthritis patients
- Trial name
- NCT07003451
- Testing
- Calprotectin Level
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
COVID-19, Long COVID
BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe…
- Conditions
- COVID-19, Long COVID, Pulmonary Fibrosis, Post-acute Respiratory Complications of COVID-19
- Trial name
- NCT04482595
- Testing
- BIO 300 Oral Suspension
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Humanetics Corporation
Idiopathic Pulmonary Fibrosis
NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib
To better understand the clinical characteristics of Idiopathic Pulmonary Fibrosis (IPF) / Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)/ Progressive Fibrosing Interstitial Lung Disease (PF-ILD) patients…
- Trial name
- NCT04614441
- Testing
- OFEV®
- Where
- 26 sites in Taiwan
- Volunteers
- 214 people
- Sponsor
- Boehringer Ingelheim
COPD, Interstitial Lung Disease
Autologous Stem Cell Treatment for Chronic Lung Disease Study
The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient the same day.
- Trial name
- NCT03044431
- Testing
- Cell therapy
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Lung Institute
Chronic Obstructive Pulmonary Disease, Pulmonary Fibrosis
Using Health-related Quality of Life (HRQL) in Routine Clinical Care
The objective of this study is to assess the effects of using HRQL measures in the clinical care of pre- and post-lung transplant patients.
- Conditions
- Chronic Obstructive Pulmonary Disease, Pulmonary Fibrosis, Pulmonary Hypertension, Cystic Fibrosis
- Trial name
- NCT00457301
- Testing
- HUI score card
- Where
- Canada
- Volunteers
- 213 people
- Sponsor
- University of Alberta
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
Effects of Pulmonary Rehabilitation on Walking Speed in Patients With COPD or ILD Patients
The aim of this study is to evaluate the effects of a three-week inpatient pulmonary rehabilitation (PR) program on the walking speed in patients with chronic obstructive (COPD) or interstitial lung disease (ILD).
- Trial name
- NCT04159129
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Schön Klinik Berchtesgadener Land
Idiopathic Pulmonary Fibrosis
(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
The ARTEMIS-IPF study was conducted to determine if ambrisentan was effective in delaying disease progression and death in participants with idiopathic pulmonary fibrosis (IPF), to evaluate its safety, and to evaluate its effect…
- Trial name
- ARTEMIS-IPF (NCT00768300)
- Testing
- Ambrisentan
- Where
- 185 sites in United States, Argentina and 20 more
- Volunteers
- 494 people
- Sponsor
- Gilead Sciences
Idiopathic Pulmonary Fibrosis
Inspiratory Effort and Respiratory Mechanics in Spontaneously Breathing Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Matched Control Study
Idiopathic pulmonary fibrosis is a life-threatening lung disease characterized by progressive deterioration of lung function and a median survival time of 3-5 years from diagnosis.
- Trial name
- IERATIC (NCT05313672)
- Volunteers
- 20 people
- Sponsor
- Roberto Tonelli
Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF)
Finger Versus Earlobe Pulse Oximetry During the 6-Minute Walk Test in Interstitial Lung Disease
The OXISITE-ILD study is a prospective, multicenter, observational study designed to evaluate the agreement between finger (digital) and earlobe (auricular) pulse oximetry for measuring oxygen saturation (SpO2) during the…
- Conditions
- Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis, Connective Tissue Disease-Associated Interstitial Lung Disease
- Trial name
- OXISITE-ILD (NCT07723872)
- Testing
- Dual-site pulse oximetry (finger and earlobe)
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Hospital de Granollers
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML)
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
The purpose of this study is to learn more about the effects of (classification determinant) CD34+ stem cell selection on graft versus host disease (GVHD) in children, adolescents, and young adults.
- Conditions
- Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML)
- Trial name
- NCT02061800
- Testing
- CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Diane George
Idiopathic Pulmonary Fibrosis
Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis
This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of garadacimab in subjects with idiopathic…
- Trial name
- NCT05130970
- Testing
- Garadacimab
- Where
- 47 sites in United States, Australia and 9 more
- Volunteers
- 81 people
- Sponsor
- CSL Behring
Scleroderma, Interstitial Lung Disease
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma is a rare, long-term autoimmune disease in which normal tissue is replaced with dense, thick fibrous tissue. Normally, the immune system helps defend the body against disease and infection.
- Trial name
- SLSII (NCT00883129)
- Testing
- Mycophenolate mofetil, Cyclophosphamide
- Where
- 14 sites in United States
- Volunteers
- 142 people
- Sponsor
- Michael Roth
Rheumatoid Arthritis, Interstitial Lung Disease
Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA).
- Trial name
- RAPID (NCT03297775)
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- University of Colorado, Denver
Interstitial Lung Disease
Interstitial Lung Disease Within a Lung Cancer Screening
Interstitial lung disease is a devastating lung condition with terrible outcomes. Lung cancer is the world's leading cause of cancer related death.
- Trial name
- ILD (NCT04715347)
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Manchester University NHS Foundation Trust
the Relationship Between the Tumor Markers and Interstitial Lung Disease Patients
The Relationship Between the Tumor Markers and Interstitial Lung Disease
The serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA125 are often increased in interstitial lung disease patients.
- Trial name
- NCT04597814
- Testing
- No Intervention
- Where
- China
- Volunteers
- 13 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.